| Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7 … ET Ogburn, DR Jones, AR Masters, C Xu, Y Guo, Z Desta Drug Metabolism and Disposition 38 (7), 1218-1229, 2010 | 180 | 2010 |
| Stereoselective and regiospecific hydroxylation of ketamine and norketamine Z Desta, R Moaddel, ET Ogburn, C Xu, A Ramamoorthy, SLV Venkata, ... Xenobiotica 42 (11), 1076-1087, 2012 | 118 | 2012 |
| The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents WJ Lu, C Xu, Z Pei, AS Mayhoub, M Cushman, DA Flockhart Breast cancer research and treatment 133, 99-109, 2012 | 92 | 2012 |
| Effects of the CYP2B6* 6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 … C Xu, ET Ogburn, Y Guo, Z Desta Drug Metabolism and Disposition 40 (4), 717-725, 2012 | 79 | 2012 |
| Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms WJ Lu, V Ferlito, C Xu, DA Flockhart, S Caccamese Chirality 23 (10), 891-896, 2011 | 74 | 2011 |
| Local Luminosity Function at 15 Microns and Galaxy Evolution Seen by ISOCAM 15 Micron Surveys C Xu The Astrophysical Journal 541 (1), 134, 2000 | 72 | 2000 |
| In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19 C Xu, Z Desta Drug metabolism and pharmacokinetics 28 (4), 362-371, 2013 | 55 | 2013 |
| Standard error estimation using the EM algorithm for the joint modeling of survival and longitudinal data C Xu, PD Baines, JL Wang Biostatistics 15 (4), 731-744, 2014 | 38 | 2014 |
| CYP2B6 pharmacogenetics–based in vitro–in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling C Xu, SK Quinney, Y Guo, SD Hall, L Li, Z Desta Drug Metabolism and Disposition 41 (12), 2004-2011, 2013 | 32 | 2013 |
| Semi-parametric joint modeling of survival and longitudinal data: the r package JSM C Xu, PZ Hadjipantelis, JL Wang Journal of Statistical Software 93, 1-29, 2020 | 14 | 2020 |
| Semiparametric Analysis of Incomplete Survival Data C Xu University of California, Davis, 2014 | 1 | 2014 |
| Improved Estimation and Uncertainty Quantification Using Monte Carlo-based Optimization Algorithms C Xu, P Baines, JL Wang Journal of Computational and Graphical Statistics 24 (3), 771-791, 2015 | | 2015 |
| Mechanisms and quantitative prediction of efavirenz metabolism, pharmacogenetics and drug interactions C Xu Indiana University, 2013 | | 2013 |
| GENOTYPE-BASED IN VITRO-IN VIVO EXTRAPOLATION (IVIVE) OF EFAVIRENZ PHARMACOKINETICS USING A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL C Xu, S Quinney, Y Guo, Z Desta CLINICAL PHARMACOLOGY & THERAPEUTICS 91, S30-S30, 2012 | | 2012 |
| INHIBITORY EFFECT OF EFAVIRENZ ON CYP2C8-CATALYZED AMODIAQUINE N-DESETHYLATION IN VITRO C Xu, Z Desta CLINICAL PHARMACOLOGY & THERAPEUTICS 89, S15-S15, 2011 | | 2011 |
| The Far-Infrared and Ultraviolet Emissions of Nearby Galaxies as a Probe of a Low Extinction V Buat, D Burgarella, C Xu Science With The NGST 133, 209, 1998 | | 1998 |
| The far infrared and ultraviolet emission from nearby galaxies as probes of a low extinction V Buat, D Burgarella, C Xu AIP Conference Proceedings 408 (1), 379-384, 1997 | | 1997 |
| The Extinction in Galactic Disks from a Multiwavelength Study V Buat, C Xu Astronomie Extragalactique Dans L'infrarouge 17, 203, 1997 | | 1997 |
| Extinction and Dust Column Density in Spiral Disks from FIR vs. UV-Optical Comparison C Xu, V Buat New Extragalactic Perspectives in the New South Africa: Proceedings of the …, 1996 | | 1996 |
| Subject headings: galaxies: general–infrared: sources–radio sources: galaxies–stars: formation–ultraviolet: general C XU THE ASTROPHYSICAL JOURNAL 365, L47-L50, 1990 | | 1990 |
